We aimed to evaluate the ability of deep learning (DL) models to identify patients from a paired chest radiograph (CXR) and compare their performance with that of human experts. In this retrospective study, patient identification DL models were developed using 240,004 CXRs. The models were validated using multiple datasets, namely, internal validation, CheXpert, and Chest ImaGenome (CIG), which include different populations. Model performance was analyzed in terms of disease change status. The performance of the models to identify patients from paired CXRs was compared with three junior radiology residents (group I), two senior radiology residents (group II), and two board-certified expert radiologists (group III). For the reader study, 240 patients (age, 56.617 ± 13.690 years, 113 females, 160 same pairs) were evaluated. A one-sided non-inferiority test was performed with a one-sided margin of 0.05. SimChest, our similarity-based DL model, demonstrated the best patient identification performance across multiple datasets, regardless of disease change status (internal validation [area under the receiver operating characteristic curve range: 0.992-0.999], CheXpert [0.933-0.948], and CIG [0.949-0.951]). The radiologists identified patients from the paired CXRs with a mean accuracy of 0.900 (95% confidence interval: 0.852-0.948), with performance increasing with experience (mean accuracy:group I [0.874], group II [0.904], group III [0.935], and SimChest [0.904]). SimChest achieved non-inferior performance compared to the radiologists (P for non-inferiority: 0.015). The findings of this diagnostic study indicate that DL models can screen for patient misidentification using a pair of CXRs non-inferiorly to human experts.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10278-024-01245-0 | DOI Listing |
Patient
January 2025
Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Background: In the context of injectable biologic products approved or in development for chronic spontaneous urticaria (CSU), it is important to capture which treatment attributes matter most to patient and what trade-offs patients are willing to make.
Objectives: The CHOICE-CSU study aimed to quantify patient preferences toward injectable treatment attributes among patients with CSU, inadequately controlled by H1-antihistamines.
Methods: This was a two-phase cross-sectional patient preference study in adult patients with a diagnosis of CSU, inadequately controlled by H1-antihistamines.
Br J Radiol
January 2025
Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Theranostics has its roots with the first radioiodine therapy for thyroid diseases in about 80 years ago. More recently the field has experienced a remarkable renascence with the regulatory approval of paired imaging and radiopharmaceutical therapy agents in gastroenteropancreatic neuroendocrine tumors and metastatic castration-resistant prostate cancer that are now employed in routine clinical practice. The momentum is strong for identification and testing of new theranostic agents for use in various cancers and finding new clinical incications of the available agents.
View Article and Find Full Text PDFAntimicrob Agents Chemother
January 2025
Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Paired baseline and post-exposure isolates from 34 patients who developed ceftolozane-tazobactam (TOL-TAZ) resistance following treatment of multidrug-resistant (MDR) infections were analyzed to determine if ceftolozane with an alternative β-lactamase inhibitor could restore susceptibility. The median baseline TOL-TAZ MIC was 2 mg/L; 88% of post-exposure isolates harbored new mutations. Median MIC fold-increase from baseline was 32-, 24-, 16-, and 6-fold for ceftolozane-tazobactam, ceftolozane-avibactam (AVI), ceftolozane-relebactam (REL), and ceftolozane-durlobactam (DUR), respectively.
View Article and Find Full Text PDFInt J Med Educ
January 2025
Department of Medicine, Vanderbilt University Medical Center, USA.
Objectives: We aimed to determine if shared decision-making (SDM) self-assessment of a standardized patient (SP) scenario was reliable, specifically whether students' communication resulted in each SP-student pair reporting internally consistent final treatment choices. We hypothesized student self-assessment would differ from SP and faculty assessment indicating a need for multisource feedback.
Methods: In this observational case study from 2016-2017, all third-year post-clerkship medical students received evidence-based treatment options for sinusitis and SDM lectures followed by a SP encounter on sinusitis.
Front Cardiovasc Med
January 2025
Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, China.
Background: Acute myocardial infarction (AMI), a subset of acute coronary syndrome, remains the major cause of mortality worldwide. Mitochondrial dysfunction is critically involved in AMI progression, and mitophagy plays a vital role in eliminating damaged mitochondria. This study aimed to explore mitophagy-related biomarkers and their potential molecular basis in AMI.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!